Novo Nordisk to discontinue Levemir insulin in U.S. market
(Reuters) – Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker said supply…
